Comparing the current results to its competitors, Qiagen N V reported Revenue increase in the 4 quarter 2025 by 6 % year on year. The revenue growth was below Qiagen N V 's competitors' average revenue growth of 7.13 %, achieved in the same quarter.
September 11, 2025
QIAGEN Achieves CE-IVDR Certification for QIAstat-Dx Portfolio While Expanding Oncology Offerings Through Strategic Partnerships for MRD TestingIn a significant advancement for molecular diagnostics, QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has secured European CE-IVDR certification for its entire portfolio of QIAstat-Dx syndromic testing systems and panels. This encompasses an enhanced Meningitis/Encephalitis (ME) Panel, which represents a new gold standard in diagnosing central nervous system (CNS) infections. The QIAstat-Dx system now boasts CE-IVDR certified panels not only for CNS infections but also for respiratory and gastrointestinal pathogens, thus offering clinicians a comprehensive suite...
May 23, 2025
VENLO, Netherlands QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a front-runner in molecular testing solutions, is making strategic strides to enhance the landscape of oncology research and global health. Through notable partnerships, cutting-edge product launches, and upcoming technological advancements, this life sciences giant is steadfast in its mission to deliver groundbreaking solutions for cancer research, disease detection, and laboratory automation worldwide. Expanding Oncology Research with ID Solutions In an ambitious effort to fortify its position in oncology research, QIAGEN has announced a strategic partnership with ID Solutions, a French innovator in high-quality digital PCR (dPCR...
November 27, 2024
As the landscape of molecular diagnostics continues to evolve, QIAGEN N.V. is making waves with the introduction of groundbreaking tools tailored for microbial analysis. The company s recent launch of customizable digital PCR assay design tools and advanced NGS panels marks a significant milestone in the realm of precision diagnostics. Revolutionizing Microbial Applications with Custom Tools QIAGEN has unveiled the market s first customizable digital PCR (dPCR) assay design tool, a first-of-its-kind innovation that leverages sophisticated design algorithms tailored for diverse microbial applications. This novel tool offers unparalleled flexibility in digital PCR analysis, catering specifically to the charact...
November 12, 2024
QIAGEN Advances Microbiome and Diagnostic Research through Strategic Collaborations and Innovations VENLO, Netherlands. QIAGEN, a leader in molecular diagnostics and sample preparation technology, is making significant strides in both microbiome research and diagnostic testing through its collaboration with McGill University and ongoing expansion of its FDA-cleared test portfolio. These initiatives underscore QIAGEN s commitment to advancing research and diagnostics that have tangible impacts on medicine and public health. Collaboration with McGill University: A Leap in Microbiome ResearchQIAGEN has announced a strategic partnership with McGill University to advance research in the microbiome, which is i...
November 4, 2024
In a pivotal development for emergency diagnostics, QIAGEN has received clearance from the U.S. Food and Drug Administration (FDA) for its QIAstat-Dx Meningitis/Encephalitis Panel. This innovative tool is designed to facilitate the diagnosis of central nervous system infections in clinical settings, marking a significant advancement in patient care.This latest FDA clearance is the fourth for QIAstat-Dx products in 2024, underscoring QIAGEN s commitment to expanding its diagnostic capabilities for the U.S. market. With this clearance, the company now provides a comprehensive menu of FDA-approved tests that cover a range of infectious diseases, including respiratory and gastrointestinal infections, in addition...
October 10, 2024
As QIAGEN N.V. prepares to release its third-quarter results for 2024, the company is already making waves in the clinical diagnostics industry with groundbreaking technological advancements. Headquartered in Venlo, The Netherlands, QIAGEN is listed on both the New York Stock Exchange (NYSE: QGEN) and the Frankfurt Stock Exchange (QIA). The unveiling of their QIAcuityDx digital PCR system and the PreAnalytiX joint venture s PAXgene Urine Liquid Biopsy Set marks significant milestones that reinforce QIAGEN s commitment to expanding its innovative reach in the healthcare sector. The QIAcuityDx Breakthrough QIAGEN has introduced the QIAcuityDx digital PCR (Polymerase Chain Reaction) system, designed explicitly ...
October 7, 2024
The year 2024 marks a crucial point in the global fight against tuberculosis (TB), as experts, policymakers, and industry leaders gather for the Global TB Summit. Once considered a disease of the past in many parts of the world, tuberculosis is resurfacing as a leading infectious killer, demanding renewed attention and collaborative approaches to tackling its spread. The summit serves as a clarion call for urgency, innovation, and cooperation among stakeholders to address this burgeoning global health challenge.A succession of factors ranging from the COVID-19 pandemic s diversion of healthcare resources to the growing antibiotic resistance crisis has contributed to the resurgence of TB. According to recent ...
September 26, 2024
Vilnius, Lithuania, Sept. 26, 2024 Oxylabs, a leading platform in web intelligence collection, has announced the release of a groundbreaking artificial intelligence solution aimed at revolutionizing the way enterprises gather public web data. The new AI-driven tool, named OxyCopilot, is designed to streamline the complex and often resource-intensive task of web scraping, promising significant time and cost savings for its users.OxyCopilot is the industry s first AI assistant specifically tailored for web scraping. Integrated into Oxylabs existing Web Scraper API, the new solution leverages advanced AI algorithms to automate and enhance various aspects of data acquisition. This includes intelligent identif...
June 12, 2024
QIAGEN Achieves ESG Milestones and Advances Product Portfolio Amid Strategic ShiftsIn a robust demonstration of its commitment to environmental, social, and governance (ESG) principles, QIAGEN has published its 2023 sustainability report, encapsulating significant progress in its sustainability goals. These achievements come alongside strategic moves in its product portfolio designed to meet the evolving needs of the market and further solidify its position as a trusted partner in the biopharma industry. ESG Commitments: Strategic Investments for Stakeholder Value Environmental Initiatives QIAGEN has made salient strides in reducing its environmental footprint. The company reported a 15% reduction in Scope ...
May 29, 2024
QIAGEN Advances Precision Medicine with Innovative Library Preparation Kit and Respiratory Testing PanelIn a significant breakthrough for the field of precision medicine, QIAGEN recently launched its QIAseq Multimodal DNA/RNA Lib Kit, a groundbreaking solution that enables streamlined DNA and RNA library preparation for next-generation sequencing from a single sample. This new kit has the potential to revolutionize multiomic studies and Comprehensive Genomic Profiling (CGP), offering researchers high flexibility and sensitivity while saving valuable sample material and time.Understanding complex diseases such as cancer requires a comprehensive approach that encompasses multiple molecular layers. By facilitat...
Standard Biotools Inc operates as a biotechnology company that specializes in the development and distribution of standard laboratory tools and reagents. They offer a diverse range of high-quality products including lab equipment, molecular diagnostics, and research reagents to meet the needs of scientists and researchers in the life sciences industry. With a customer-centric approach, Standard Biotools aims to provide reliable and affordable solutions to support advancements in scientific research and discovery.
Maravai Lifesciences Holdings Inc's business model revolves around providing integrated solutions for the development and manufacturing of biopharmaceutical products.
Pacific Biosciences Of California Inc Share Performance
+15.32%
30 Days
Pacific Biosciences Of California Inc
Profile
Pacific Biosciences of California Inc's business model revolves around the development and commercialization of innovative sequencing systems that enable scientists and researchers to study the complexity of biology. They provide high-resolution genetic analysis solutions, offering a comprehensive platform that includes consumables, systems, and data analysis software to support genomic analysis.
Repligen Corp operates as a bioprocessing company that provides products and services to the life sciences industry. They focus on the development, production, and distribution of highly specialized consumable products used in the manufacture of biological drugs. Repligen's business model revolves around helping their customers enhance productivity, improve quality, and reduce production costs in the biopharmaceutical manufacturing process.
Sources:
Qiagen N v’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Qiagen N v versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
